Akari CEO Says Synthetic Royalties May Be Used To Fund Coversin Trials

Akari Therapeutics will explore novel funding options to pay for Phase III trials of Coversin, its lead asset, derived from a native protein discovered in the saliva of the Ornithodoros moubata tick.